Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Headquartered in New York, Pfizer has been the world's largest research-based pharmaceutical company since it stole Merck & Co's crown in 1998. The subsequent acquisition of Warner-Lambert (and with it Agouron) in June 2000 and the merger with Pharmacia in April 2003 (which included the former Monsanto division, GD Searle) cemented this position and it looks unlikely to be toppled in the near future. Employing around 98,000 people worldwide, it has more than 100 overseas subsidiaries and operations in around 150 countries.

Pfizer has a broad portfolio, with strengths in the areas of cardiovascular disease, central nervous system disorders, inflammatory disease, metabolic disorders, infectious diseases and oncology. In 2004, Pfizer set an industry record with ten of its products (including Celebrex) generating revenues of more than US$1 billion each; in 2006 this number has been reduced to nine.

Pfizer is executing a wide-ranging strategy to transform all areas of its business, grow current and new medicines, drive productivity improvements and launch innovative patient-centered healthcare initiatives. To address the challenges for 2007, Pfizer is making efforts to sustain in-line product growth and to launch a new wave of innovative medicines, using relationships with partner companies where necessary.

Addressing financial analysts in February 2006, Pfizer outlined its drivers of value for 2006-2008, including growth of its key in-line medicines, an increasingly substantial contribution from new medicines, enhanced R&D productivity supporting a broad and promising pipeline of new medicines, and streamlining to reduce costs and speed decision-making in all parts of the company.

Pfizer expects to see sustained growth from key medicines and an increasingly large contribution from new medicines, which will offset the impact of loss of exclusivity for its older products. The company is re-allocating resources to ensure the highest growth from its portfolio of important medicines.